Navigation Links
Studies show LAM patients participate in clinical trials to help others, not themselves
Date:5/14/2009

CINCINNATITwo recent studies by researchers at the University of Cincinnati (UC) bring to light interesting findings about the diagnosis of the rare lung disease Lymphangioleiomyomatosis ( LAM) and the reasons LAM patients participate in research studies.

Brent Kinder, MD, Frank McCormack, MD, and Jared Hagaman, MD, working with colleagues in the division of pulmonary, critical care and sleep medicine at UC, found that patients with LAM were more likely to participate in clinical trials because of a shared cause and a feeling of altruism, as opposed to personal benefit.

In addition, this team found that CT scans given to young women who come to the emergency room for the first time with a collapsed lung are cost-effective and beneficial.

These findings will be presented at the American Thoracic Society International Conference in San Diego May 15-20.

LAM is a rare but serious lung disease that occurs when an unusual type of cell begins to grow out of control and spread to restricted areas in the body, including the lungs, kidneys, lymph nodes and vessels.

In the first study, 918 LAM patients in North America were surveyed to determine who participated in clinical trials and why. Of the 918 surveyed, 263 patients responded.

"Age, disease duration, use of oxygen therapy and disease presentation without chest pain were associated with trial participation, but the desire to help others with similar health problems was at the top of list," says Kinder, also director of the Interstitial Lung Disease Center at UC.

Results showed that 16 percent of LAM patient respondents participated in a clinical trial, but 85 percent of those people participated to help future patients.

In addition, results showed that the usual barriers to trial participation, like time constraints, risk of taking a placebo and geographic location, were found to be less important for LAM patients.

In a separate study, Kinder and colleagues found that it is cost-effective to do CT scan screening of non-smoking women, ages 25-54, who come to the emergency room for the first time with a collapsed lungan early predictor of LAMin order to diagnose and treat those with the illness.

"A major contributor to morbidity in patients with LAM is spontaneous pneumothorax, or a collapsed lung," Kinder says. "Seventy percent of patients with LAM will have at least one and most will have one or more recurrences. Due to lack of awareness and non-specific nature of most symptoms, the diagnosis of LAM is often delayed for several years into the disease.

"A CT scan for women of child-bearing age who experience a collapsed lung could help with a faster diagnosis, thereby improving outcomes."

Kinder says the results of these studies can help identify the disease in its early stages and find more effective treatments for patients with LAM.

"The more quickly we can detect the illness, the better chance a patient has of prolonging her life in addition to introducing the patient to novel therapies through clinical trials, which could help others as well," he says.


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Traumatic brain injury haunts children for years with variety of functional problems: Two studies
2. Review finds conflicts of interest in many cancer studies
3. Studies Report Use of USGI Medicals Incisionless Operating Platform(TM) (IOP) in Numerous Incisionless Surgical Procedures
4. Physicians Conduct Research Studies in Minutes, Not Months, at Montefiore Medical Center
5. Kessler Foundation Research Center Presented Two Studies on Post-stroke Spatial Neglect at American Academy of Neurology
6. Studies uncover high and often overlooked costs associated with epilepsy
7. Are we cherry picking participants for studies of antidepressants?
8. Wound Management Technologies, Inc. Announces the Presentation of Evidence Based Clinical Studies at the Symposium on Advanced Wound Care Conference in Dallas
9. Pharos Innovations and Clients to Showcase Three Client Case Studies at Upcoming ATA Conference
10. Gene Studies Reveal Cancers Secrets
11. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ... communities in the greater Dallas, Miami, and Raleigh regions, is organizing an extended ... overcome a rare and deadly chromosome abnormality. , After struggling since birth with ...
(Date:10/13/2017)... ... October 13, 2017 , ... The ... to promote standards of excellence for the field of eating disorders, announces the ... – 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
Breaking Medicine Technology: